🇺🇸 FDA
Patent

US 12083141

Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

granted A61KA61K31/7105A61K33/30

Quick answer

US patent 12083141 (Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/7105, A61K33/30